Insulin action and secretion in hypertension in the absence of metabolic syndrome: model-based assessment from oral glucose tolerance test

Metabolism: Clinical and Experimental

Volumn 58, Issue 1, 2009, Pages 80-92

  Burattini, Roberto ^a   Di Nardo, Francesco ^a   Casagrande, Fabrizio ^a   Boemi, Massimo ^b   Morosini, Pierpaolo ^c  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

^c Mazzoni Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; INSULIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 57049176020     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.08.010     Document Type: Article

References (44)

1. Ferrannini E., Buzzigoli G., Bonadonna R., Giorico M.A., Oleggini M., Graziadei L., et al. Insulin resistance in essential hypertension. N Engl J Med 317 (1987) 350-357
2. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
3. Pollare T., Lithell H., and Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 39 (1990) 167-174
4. Salvatore T., Cozzolino D., Giunta R., Giugliano D., Torella R., and D'Onofrio F. Decreased insulin clearance as a feature of essential hypertension. J Clin Endocrinol Metab 74 (1992) 144-149
5. Giugliano D., Quatraro A., Minei A., De Rosa N., Coppola L., and D'Onofrio F. Hyperinsulinemia in hypertension: increased secretion, reduced clearance or both?. J Endocrinol Invest 16 (1993) 315-321
6. Kautzky-Willer A., Pacini G., Weissel M., Capek M., Ludvik B., and Prager R. Elevated hepatic insulin extraction in essential hypertension. Hypertension 21 (1993) 646-653
7. Swislocki A.L. Impaired insulin clearance in essential hypertension. J Hum Hypertens 8 (1994) 185-190
8. Ferrannini E., Natali A., Capaldo B., Lehtovirta M., Jacob S., and Yki-Järvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 30 (1997) 1144-1149
9. Lender D., Arauz-Pacheco C., Adams-Huet B., and Raskin P. Essential hypertension is associated with decreased insulin clearance and insulin resistance. Hypertension 29 (1997) 111-114
10. Zavaroni I., Bonini L., Gasparini P., Barilli A.L., Zuccarelli A., Dall'Aglio E., et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension and coronary heart disease. The Barilla factory revisited. Metabolism 48 (1999) 989-994
11. Wiggam M.I., Hunter S.J., Armstrong V.L., Ennis C.N., Sheridan B., Atkinson A.B., et al. Insulin resistance and insulin pulsatility in essential hypertension. J Hypertens 18 (2000) 743-748
12. Grandi A.M., Zanzi P., Broggi R., Fachinetti A., Guasti L., Ceriani L., et al. Longitudinal changes of insulin sensitivity in essential hypertension: influence of blood pressure control and familial predisposition to hypertension. J Clin Endocrinol Metab 86 (2001) 3027-3031
13. Natalucci S., Boemi M., Fumelli D., Fumelli P., and Burattini R. Interaction between glucose metabolism and endogenous insulin release in hypertension. Metabolism 51 (2002) 297-303
14. Chen H., Sullivan G., Yue L.Q., Katz A., and Quon M.J. QUICKI is a useful index of insulin sensitivity in subjects with hypertension. Am J Physiol Endocrinol Metab 284 (2003) E804-E812
15. Reaven G.M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 88 (2003) 2399-2403
16. Burattini R., Di Nardo F., Boemi M., and Fumelli P. Deterioration of insulin sensitivity and glucose effectiveness with age and hypertension. Am J Hypertens 19 (2006) 98-102
17. Grundy S.M. Hypertriglyceridemia, atherogenic dyslipidemia and the metabolic syndrome. Am J Cardiol 81 (1998) 18B-25B
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
19. Bergman R.N., Phillips L.S., and Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68 (1981) 1456-1467
20. Kahn S.E., Prigeon R.L., McCulloch D.K., Boyko E.J., Bergman R.N., Schwartz M.W., et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42 (1993) 1663-1672
21. Breda E., Cavaghan M.K., Toffolo G., Polonsky K.S., and Cobelli C. Oral glucose tolerance test minimal model indexes of β-cell function and insulin sensitivity. Diabetes 50 (2001) 150-158
22. Ferrannini E., and Mari A. Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 47 (2004) 943-956
23. Mari A., Ahrén B., and Pacini G. Assessment of insulin secretion in relation to insulin resistance. Curr Opin Clin Nutr Metab Care 8 (2005) 529-533
24. Cobelli C., Toffolo G.M., Dalla Man C., Campioni M., Denti P., Caumo A., et al. Assessment of β-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 293 (2007) E1-E15
25. Bergman R.N., Ider Y.Z., Bowden C.R., and Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 236 (1979) E667-E677
26. Eaton R.P., Allen R.C., Schade D.S., Erickson K.M., and Standfer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behaviour. J Clin Endocrinol Metab 51 (1980) 520-528
27. Van Cauter E., Mestrez F., Sturis J., and Polonsky K.S. Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41 (1992) 368-377
28. Toffolo G., De Grandi F., and Cobelli C. Estimation of β-cell sensitivity from intravenous glucose tolerance test C-peptide data. Knowledge of the kinetics avoids errors in modelling the secretion. Diabetes 44 (1995) 845-854
29. Muscelli E., Mari A., Natali A., Astiarraga B.D., Camastra S., Frascerra S., et al. Impact of incretin hormones on β-cell function in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab 291 (2006) E1144-E1150
30. Campioni M., Toffolo G., Shuster L.T., Service F.J., Rizza R.A., and Cobelli C. Incretin effect potentiates β-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study. Am J Physiol Endocrinol Metab 292 (2007) E54-E60
31. Toffolo G., Breda E., Cavaghan M.K., Erhmann D.A., Polonsky K.S., and Cobelli C. Quantitative indexes of beta-cell function during graded up & down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab 280 (2001) E2-E10
32. Dalla Man C., Campioni M., Polonsky K.S., Basu R., Rizza R.A., Toffolo G., et al. Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of β-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes 54 (2005) 3265-3273
33. Caumo A., Bergman R.N., and Cobelli C. Insulin sensitivity from meal tolerance tests in normal subjects: a minimal model index. J Clin Endocrinol Metab 85 (2000) 4396-4402
34. Di Nardo F., Casagrande F., Boemi M., Fumelli P., Morosini P., and Burattini R. Insulin resistance in hypertension quantified by oral glucose tolerance test: comparison of methods. Metabolism 55 (2006) 143-150
35. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
36. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., and Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 342 (2000) 905-912
37. Lindholm L.H., Persson M., Alaupovic P., Carlberg B., Svensson A., and Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 21 (2003) 1563-1574
38. Stas S., Appesh L., and Sowers J. Metabolic safety of antihypertensive drugs: myth versus reality. Curr Hypertens Rep 8 (2006) 403-408
39. Dalla Man C., Yarasheski K.E., Caumo A., Robertson H., Toffolo G., Polonsky K.S., et al. Insulin sensitivity by oral glucose minimal models: validation against clamp. Am J Physiol Endocrinol Metab 289 (2005) E954-E959
40. Carson E.R., Cobelli C., and Finkelstein L. The mathematical modeling of metabolic and endocrine systems (1983), Wiley, New York
41. Barrett P.H., Bell B.M., Cobelli C., Golde H., Schumitzky A., Vicini P., et al. SAAM II: simulation, analysis, and modeling software for tracers and pharmacokinetics studies. Metabolism 47 (1998) 484-492
42. Toffolo G., Campioni M., Basu R., Rizza R.A., and Cobelli C. A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction. Am J Physiol Endocrinol Metab 290 (2006) E169-E176
43. Bergman R.N. Pathogenesis and prediction of diabetes mellitus: lessons from integrative physiology. Mt Sinai J Med 69 (2002) 280-290
44. Lilliefors H.W. On the Kolmogorov-Smirnov test for normality with mean and variance unknown. J Am Stat Assoc 62 (1967) 399-402